Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U02 Substudy 02A: Investigational Agents with Pembrolizumab in PD-1 Refractory Melanoma
NCT04305041Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2020
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of pembrolizumab, quavonlimab, vibostolimab, lenvatinib, tretinoin in melanoma, sponsored by Merck & Co.. Started Jun 2020; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04305041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305041.